Literature DB >> 13364378

Dextran sulphate: use as an anticoagulant, and action in lowering serum cholesterol.

H COHEN, G R TUDHOPE.   

Abstract

Entities:  

Keywords:  BLOOD COAGULATION/effect of drugs on; CHOLESTEROL/in blood; DEXTRAN/effects

Mesh：

Substances：

Year:  1956        PMID： 13364378      PMCID： PMC2035700          DOI： 10.1136/bmj.2.5000.1023

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  23 in total

1.  Clearing of lipemic plasma by heparin; duration of effect and other studies.

Authors:  J P UTZ; F D MANN; N W BARKER
Journal:  Proc Staff Meet Mayo Clin       Date:  1953-09-23

2.  Spontaneous and induced variations in serum lipoproteins.

Authors:  H L CHANDLER; E Y LAWRY; K G POTEE; G V MANN
Journal:  Circulation       Date:  1953-11       Impact factor: 29.690

3.  Therapeutic trial of the synthetic heparin analogue dextran sulphate.

Authors:  C R RICKETTS; K W WALTON; B D VAN LEUVEN; A BIRBECK; A BROWN; A C KENNEDY; C C BURT
Journal:  Lancet       Date:  1953-11-14       Impact factor: 79.321

4.  The heparin-like action of treburon in abolishing alimentary lipemia in normal individuals.

Authors:  R F ACKERMAN; D B ZILVERSMIT
Journal:  Circulation       Date:  1953-04       Impact factor: 29.690

5.  The clearing by heparin of alimentary lipaemia in coronary artery disease.

Authors:  M F OLIVER; G S BOYD
Journal:  Clin Sci       Date:  1953       Impact factor: 6.124

6.  Serum lipids studied by electrophoresis on paper.

Authors:  I N ROSENBERG
Journal:  Proc Soc Exp Biol Med       Date:  1952 Aug-Sep

7.  ABOLISHMENT OF ALIMENTARY LIPEMIA FOLLOWING INJECTION OF HEPARIN.

Authors:  P F Hahn
Journal:  Science       Date:  1943-07-02       Impact factor: 47.728

8.  Preliminary studies of a new anticoagulant drug.

Authors:  D A SCHOLZ; N W BARKER
Journal:  Proc Staff Meet Mayo Clin       Date:  1952-08-13

9.  Effect of heparin and treburon in postprandial hyperlipemia.

Authors:  W J ZINN; J B FIELD; G C GRIFFITH
Journal:  Proc Soc Exp Biol Med       Date:  1952-06

10.  Effect of heparin on plasma lipid partition in man: studies in normal persons and in patients with coronary atherosclerosis, nephrosis and primary hyperlipemia.

Authors:  J HERZSTEIN; C I WANG; D ALDERSBERG
Journal:  Ann Intern Med       Date:  1954-02       Impact factor: 25.391
View more
  10 in total

1.  Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis.

Authors:  J C ALLEN; J H BAXTER; H C GOODMAN
Journal:  J Clin Invest       Date:  1961-03       Impact factor: 14.808

2.  Alopecia following treatment with dextran sulphate and other anticoagulant drugs.

Authors:  G R TUDHOPE; H COHEN; R W MEIKLE
Journal:  Br Med J       Date:  1958-05-03

3.  Studies on the causal role of hypoalbuminemia in experimental nephrotic hyperlipemia.

Authors:  W HEYMANN; G NASH; C GILKEY; M LEWIS
Journal:  J Clin Invest       Date:  1958-06       Impact factor: 14.808

4.  Duration of anticoagulant effect in relation to urinary excretion of dextran sulphate.

Authors:  S M JEAVONS; C R RICKETTS; K W WALTON
Journal:  Br Med J       Date:  1956-11-03

5.  ANNOTATIONS.

Authors: 
Journal:  Br Med J       Date:  1956-11-17

6.  Dextran Sulfate as a Substitute for Heparin.

Authors: 
Journal:  Can Med Assoc J       Date:  1957-01-15       Impact factor: 8.262

7.  An investigation of the effects of 5 hydroxytryptamine ("Serotonin") on the cardiovascular system of the dog.

Authors:  J G NOBLE; E M NANSON
Journal:  Ann Surg       Date:  1959-11       Impact factor: 12.969

8.  ILB® resolves inflammatory scarring and promotes functional tissue repair.

Authors:  Lisa J Hill; Hannah F Botfield; Ghazala Begum; Omar Qureshi; Vasanthy Vigneswara; Imran Masood; Nicholas M Barnes; Lars Bruce; Ann Logan
Journal:  NPJ Regen Med       Date:  2021-01-07

9.  Formulation and evaluation of injectable dextran sulfate sodium nanoparticles as a potent antibacterial agent.

Authors:  Osama A Madkhali; Sivakumar Sivagurunathan Moni; Muhammad H Sultan; Haitham A Bukhary; Mohammed Ghazwani; Nabil A Alhakamy; Abdulkarim M Meraya; Saeed Alshahrani; Saad Saeed Alqahtani; Mohammed Ali Bakkari; M Intakhab Alam; Mohamed Eltaib Elmobark
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

10.  Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.

Authors:  Camilla Gustafsen; Ditte Olsen; Joachim Vilstrup; Signe Lund; Anika Reinhardt; Niels Wellner; Torben Larsen; Christian B F Andersen; Kathrin Weyer; Jin-Ping Li; Peter H Seeberger; Søren Thirup; Peder Madsen; Simon Glerup
Journal:  Nat Commun       Date:  2017-09-11       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.